Vogt-Koyanagi-Harada-Like Disease with Loss of Visual Acuity Due to Sunitinib Treatment Restored After Switch in Therapy: A Case Report

Overview

Journal Case Rep Ophthalmol

Specialty Ophthalmology

Date 2024 Mar 8

PMID 38456120

Authors

Mechteld C S van Olden

Yvonne de Jong-Hesse

Tessa Vollebregt

Stefanie de Groot

Saskia A C Luelmo

Marina Marinkovic

Affiliations

Soon will be listed here.

Abstract

Introduction: In this paper, we report a case of visual impairment during treatment with sunitinib in a patient with metastatic renal cell carcinoma.

Methods: Retrospective chart review was used.

Case Presentation: We describe a 74-year-old male with metastatic renal cell carcinoma who was treated with sunitinib and experienced severe loss of visual acuity due to serous retinal detachment and intraretinal fluid. Upon discontinuation of sunitinib, the retinal fluid resolved, and visual acuity was restored.

Conclusion: Serous retinal detachment has been described as a side effect of sunitinib use. Discontinuing sunitinib promptly resolved the subretinal fluid collections and restored vision.

References

Kapiteijn E, Brand A, Kroep J, Gelderblom H . Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007; 18(10):1745-7. DOI: 10.1093/annonc/mdm454. View

Jin J, Xie Y, Zhang J, Wang J, Dai S, He W . Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023; 67:100929. DOI: 10.1016/j.drup.2023.100929. View

van der Veldt A, van den Eertwegh A, Boven E . [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]. Ned Tijdschr Geneeskd. 2007; 151(20):1142-7. View

Fraunfelder F, Fraunfelder F . Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events. J Ocul Pharmacol Ther. 2018; 34(6):432-435. DOI: 10.1089/jop.2018.0019. View

Mistry S, Sudharshan S, Ganesan S, Akbar A, Biswas J . Vogt-Koyanagi-Harada disease like presentation in patients with chronic myeloid leukemia. Am J Ophthalmol Case Rep. 2018; 10:221-225. PMC: 5956718. DOI: 10.1016/j.ajoc.2018.03.010. View